Showing 2261-2270 of 7391 results for "".
Eczema Discovery; Ortho Dermatologics, Revision, Alastin Product Launches
https://practicaldermatology.com/topics/practice-management/dermwiretv-eczema-discovery-ortho-dermatologics-revision-alastin-product-launches/18353/Regeneron revealed that Dupixent generated sales of $120M within the first nine months of launch. Researchers have identified a possible treatment for moderate-to-severe atopic dermatitis: IL-22 blockade. Product launches or updates from Revision Skincare, Alastin Skincare, Ortho Dermatologics, andSkin Bugs and Travel Bugs: An Update for Clinicians
https://practicaldermatology.com/topics/general-topics/skin-bugs-and-travel-bugs-an-update-for-clinicians/20601/Skin disease is the third most common medical problem that travelers encounter. Heres' what you need to know about diagnosis and treatment.Pay it Backwards
https://practicaldermatology.com/topics/practice-management/pay-it-backwards/20640/Why do women in dermatology earn only 83 percent of what men earn?Galderma's Differin Goes OTC, CoolSculpting Approved for Upper Arms, ZO Skin Acquires ReFissa
https://practicaldermatology.com/series/dermwire-tv/galderma-s-differin-goes-otc-coolsculpting-approved-for-upper-arms-zo-skin-acquires-refissa/18549/Galderma's Differin Gel formulation of adapalene 0.1% is now available over the counter at major retail and drug stores in the US. ZELTIQ® Aesthetics' CoolSculpting is now FDA-cleared for fat reduction in the upper arms. ZO Skin Health has acquired the worldwide rights to ReFissa from Suneva MedicalHumphries to Valeant, Restylane Line Expands, 2016 Highlights
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-humphries-to-valeant-restylane-line-expands-2016-highlights/18709/The filler market in the US expands with FDA approval of Galderma's Restylane Refyne and Restalyne Define for the treatment of nasolabial folds in patients over the age of 21. The gels are manufactured with XpresHAn Technology, which allows a range of flexibility and support for varied patient needsConnecting the Dots
https://practicaldermatology.com/topics/practice-management/connecting-the-dots/20890/A guide to understanding millennials.Aubio Launches, Updates from Prescriber's Choice, BioPharmX
https://practicaldermatology.com/topics/practice-management/dermwiretv-aubio-launches-updates-from-prescriber-s-choice-biopharmx/18584/In this edition of DermWireTV, Aubio launches OTC treatment for cold sores with backing from Paul Mitchell partner. Prescriber's Choice facilitates in-office prescription dispensing. BioPharmX enrolls phase 2b trial for topical minocycline and Merz acquires ONLight Sciences, maker of PFD patch for tWelcome! 10 Steps to Integrating New Employees
https://practicaldermatology.com/topics/practice-management/welcome-10-steps-to-integrating-new-employees/20906/Strategic and fun ways to introduce the newest member of your team to your practice.When Disruption Spells Opportunity
https://practicaldermatology.com/topics/practice-management/when-disruption-spells-opportunity/20950/Making the case for teledermatology in the new millennium.Target: PASI 90
https://practicaldermatology.com/topics/psoriasis/target-pasi-90/18593/With new advancements in biologic therapy, patients are gaining more control of psoriasis. Whereas PASI 50 was once seen as a significant improvement, patients today can expect to achieve PASI 90. Can PASI 100 be far behind?